nabu.science
MethodologyAboutContact

 

  • Snapshot
  • Key Claims
  • Strengths & Limitations
  • Commentary
  • From the Authors
  • Author Note / Field Feedback
  • Dimension breakdown
  • Impact Profile
Free · About 5 minutes
Report #NBU-B12D76A3·Framework v5.9·Pipeline v0.4·Evaluated 08 Oct 2026·OECD: 3.2 Clinical medicine·Subfield: Psychiatry and Mental health·Basis: Full text·Type: Observational cohort study

Tau extent outperforms tau load as a predictor of neurodegeneration in Alzheimer's disease.

Macedo et al.Macedo, Trudel, Hosseini et al.·2026·Molecular neurodegeneration·10.1186/s13024-026-00945-1 ↗

Primary claim

Across cross-sectional and longitudinal analyses, tau extent provided superior predictive value for imaging-based neurodegeneration compared with tau load.

Supported · consistent imaging-model advantage, limited by in-sample comparisons and unresolved longitudinal sample accounting
In brief

Tau extent shows a credible imaging advantage over tau load, but unresolved longitudinal sample accounting limits confidence in the predictive comparison.

ReliabilityCaveats4 of 4 checks completeRead the 2 entries ↓
Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.
Abstract

BACKGROUND: In Alzheimer's disease (AD), tau pathology is more strongly linked to neurodegeneration than amyloid-β and better predicts brain atrophy. The spatial extent of tauopathy (SEOT) has shown promise as an earlier and more sensitive marker of AD severity than tau load, but how these complementary dimensions relate to neurodegeneration remains unclear. Here, we compared the in vivo associations of tau-PET extent versus load with cross-sectional and longitudinal neurodegeneration.

METHODS: We studied 367 participants across the healthy-aging to AD continuum (mean age 69.3 years; 61% female) from the TRIAD cohort who underwent [18F]MK-6240 tau-PET. Tau load was quantified as regional standardized uptake value ratio (SUVR), and SEOT as the proportion of abnormal voxels, within a temporal meta-region of interest (ROI) and a full-cortex ROI. Neurodegeneration markers included cortical thickness, hippocampal volume (HCV), medial temporal atrophy (MTA) visual ratings, plasma neurofilament light (NfL), and CSF total tau (t-tau). Cross-sectional associations were evaluated using multiple linear regression or covariate-adjusted Spearman correlations. We also compared local correlations of tau load and extent with cortical thickness across all cortical regions. Longitudinal predictive value for neurodegeneration was tested using linear mixed-effects models.

RESULTS: Cross-sectionally, all tau-PET metrics were significantly associated with neurodegeneration across imaging and fluid biomarkers. Full-cortex SEOT provided the best model fit for cortical thinning. SEOT outperformed tau load for associations with HCV and for predicting MTA, whereas SEOT and SUVR showed comparable associations with plasma NfL and CSF t-tau. Tau extent was equal or superior to tau load in its correlation with local cortical thickness across all cortical regions. Longitudinally, baseline full-cortex SEOT best predicted future cortical thinning, while temporal SEOT best predicted future hippocampal atrophy.

CONCLUSIONS: Across cross-sectional and longitudinal analyses, tau extent provided superior predictive value for imaging-based neurodegeneration compared with tau load. By enabling a spatially unbiased, whole-brain assessment of tau burden that accommodates heterogeneous topographies, SEOT represents a promising complementary tau-PET metric for staging and tracking disease progression in AD.

Key Claims

Primary finding · Supported

Across cross-sectional and longitudinal analyses, tau extent provided superior predictive value for imaging-based neurodegeneration compared with tau load.

Fragile — the claim's weakest requirement is that the effect exists at all. Experimental. Every point below is traceable to a quoted passage, but this forecast has not yet been validated against known replication outcomes.

consistent imaging-model advantage, limited by in-sample comparisons and unresolved longitudinal sample accounting

Abstract, Conclusions
Quote verified
Secondary · Well-supported

Full-cortex SEOT provided the best model fit for cortical thinning.

lowest AIC and higher adjusted R² across the reported cortical-thickness models

Abstract, Results; Results, Fig. 1E–F
Quote verified
Secondary · Supported

Longitudinally, baseline full-cortex SEOT best predicted future cortical thinning, while temporal SEOT best predicted future hippocampal atrophy.

mixed-model AIC advantages with sparse repeated observations and an unresolved follow-up denominator

Abstract, Results; Results, Figs. 5–6
Quote verified
Secondary · Supported

Tau extent was equal or superior to tau load in its correlation with local cortical thickness across all cortical regions.

region-wise correlations favour extent, though multiplicity handling for the regional tests is unclear

Abstract, Results; Results, Fig. 3
Quote verified
Secondary · Tentative

SEOT outperformed tau load for associations with HCV and for predicting MTA.

modest correlation differences and only one significant pairwise MTA AUC comparison

Abstract, Results; Results, Figs. 2A and 4C
Quote verified

Derived from the full evaluation — not a separate score.

Strengths · Limitations

Strengths

#contribution

Direct multi-outcome metric comparison

Tau extent and SUVR are compared head-to-head across cortical thickness, hippocampal volume, MTA ratings, fluid biomarkers, regional associations, and longitudinal trajectories. This addresses a specific uncertainty left by earlier SEOT studies.

↳ Abstract; Results, Figs. 1–6

#methodological rigour

Extensive parameter sensitivity testing

The analyses vary SEOT thresholds and reference groups, exclude temporal ceiling cases, and adjust longitudinal models for baseline neurodegeneration. The principal direction of the imaging findings is largely preserved.

↳ Results, Sensitivity Analyses; Supplementary Figs. 5–13

#reporting

Imaging and fluid results distinguished

The paper reports better comparative performance for several imaging outcomes while explicitly finding no significant advantage for plasma NfL or CSF total tau. This distinction prevents the conclusion from being generalized to every neurodegeneration marker.

↳ Abstract, Results and Conclusions; Fig. 2B–C

Limitations

#methodological rigour

Longitudinal sample count remains unresolved

The paper reports 227 participants with follow-up and 100 without follow-up from a baseline cohort of 367, leaving 40 participants unaccounted for in the attrition comparison. This directly complicates interpretation of selection into the longitudinal analysis.

↳ Results, opening paragraph; Results, Baseline Differences According to Follow-up Status

#reporting

Superiority language exceeds several comparisons

The claimed imaging advantage relies substantially on in-sample AIC, while some metric differences are small or not significant; only cortical SEOT versus cortical SUVR differed significantly in the MTA AUC comparison. The title and broad predictive wording therefore require tighter calibration.

↳ Title; Abstract; Results, Figs. 1, 4–6

#application pathway

External applicability remains narrowly demonstrated

The evidence comes from a single predominantly White Canadian cohort using one tracer and scanner platform. Threshold, reference-group, smoothing, and cross-site implementation conventions remain to be standardized and independently validated.

↳ Methods, Study Population and Neuroimaging Acquisition; Discussion, limitations

Does this match your read? Add your assessment ↓

Nabu Commentary

The direct comparison across multiple imaging outcomes and the broad sensitivity analysis support a meaningful, mid-to-high quality contribution. The strongest results are the model-fit advantages for full-cortex SEOT in cortical-thickness analyses and temporal SEOT in hippocampal trajectories. Confidence is lower for the broad superiority framing because several differences are modest or non-significant, the longitudinal models contain limited repeated observations, and the follow-up accounting is internally inconsistent. The paper is therefore persuasive as single-cohort comparative evidence but not yet as externally validated predictive performance.

Evaluate another paper

Free · About 5 minutes · Research preview

Author Note / Field Feedback

Nabu’s assessment, alongside the field’s view.

Are you an author of this paper?

Dimension breakdown

Evidence Score

Out of 5
012345
3.6±0.2

Contribution
3.8

The study directly compares tau extent and load across cross-sectional, regional, and longitudinal neurodegeneration outcomes, meaningfully extending prior SEOT work. The advance remains incremental and is demonstrated in one cohort.

Introduction, final paragraph; Results, Figs. 1–6

Here, we compared the in vivo associations of tau-PET extent versus load with cross-sectional and longitudinal neurodegeneration.

Methodological Rigour
3.5

Covariate-adjusted models, dependent-correlation tests, mixed models, and extensive threshold and reference-group sensitivities support the comparative analysis. In-sample AIC comparisons, random-intercept-only longitudinal models, selective follow-up, unclear regional multiplicity, and inconsistent sample accounting constrain execution.

Methods, Statistical Analysis; Results, Sensitivity Analyses; Results, Baseline Differences According to Follow-up Status
Reporting
3.7

The paper presents a coherent progression from metric definition to cross-sectional and longitudinal comparisons and explicitly reports the fluid-biomarker null. Precision is reduced by broad superiority language, a correlation-sign inconsistency, and longitudinal coefficients labelled standardized without clear scaling.

Abstract; Results, Fig. 2A; Results, Figs. 5–6
Positioning
3.6

The Discussion connects SEOT to prior extent research, Braak-non-conformant patterns, thresholding, smoothing, saturation, and generalizability. Its treatment of selective follow-up is less convincing because higher baseline disease burden is acknowledged but attributed partly to scheduling without recorded attrition reasons.

Discussion, paragraphs on whole-cortex SEOT and study limitations

Reliability

Caveats4 of 4 checks


Results checkNoted
  • SEOT outperformed tau load for associations with HCV and for predicting MTA: "Furthermore, all tau-PET metrics were significantly negatively correlated with hippocampal volume (all p < 0.0001)." (Results — Cross-sectional imaging markers of neurodegeneration) vs "Both temporal (rho = −0.34) and cortical (rho = −0.32) SEOT exhibited stronger correlations with hippocampal volume than temporal (rho = −0.27) and cortical (rho = 0.24) SUVR (Fig. 2A)." (Results — Cross-sectional imaging markers of neurodegeneration). The reported cortical-SUVR rho of positive 0.24 contradicts the statement that every hippocampal-volume correlation is negative, but the supplied text does not establish which report is correct. → Effect on result unclear
Reporting and transparencyNoted

Longitudinal interaction coefficients are labelled standardized without enough information to resolve their scaling across cortical-thickness and hippocampal-volume outcomes.

Ethics approval: declared · Data availability: declared

Reference IntegrityClean

68 references in manuscript 68 of 68 checkable references found in an index

References not verified automatically are resolved manually within 24 hours.

Post-Publication RecordClean

No retraction or expression of concern found in Crossref (includes Retraction Watch).

Last checked: 17 Oct 2026

Sources: Crossref (incl. Retraction Watch) ✓

Impact Profile

Impact areaHealth · Neurological · Alzheimer's disease and other dementias
Type of advanceEmpirical
Route to useSuggested
AdvanceExtends
BeneficiariesLarge
CitationsToo early
Policy · patentNot yet traced
ReachedNot reachedNot assessable or unverified
ReadinessPiloted
Foundational
Controlled
Piloted
Validated
Implementable
FoundationalImplementable

The finding is shown working in one well-characterized longitudinal cohort, but the authors themselves call for replication in other datasets before drawing firmer conclusions.

From the paper
“SEOT represents a promising complementary tau-PET metric for staging and tracking disease progression in AD”

The paper names a real-world use of SEOT—staging and tracking disease progression—but does not specify a concrete decision-maker or clinical decision that would apply it.

Pathway

Neurologists, memory clinics and trial teams could adopt SEOT as a tau-PET metric for staging and tracking Alzheimer's disease progression.

Barrier

Findings come from a single, largely White cohort with short follow-up, and SEOT thresholds are arbitrary, so independent replication and methodological standardization are needed before clinical use.

Evaluated 13 Nov 2026 · GBD 2023 · glm_v1_3_3 · impact_profile_v1_3_3

Report an issue →

AI-generated, human-governed. Something look off? Contact us to request a review.

Keep reading

Related evaluations

Other papers Nabu has evaluated blind, starting with the same field.

  1. Effect of intensive blood pressure control on cognitive outcomes and brain structures in adults with type 2 diabetes: prespecified analysis of secondary outcomes of BPROAD randomised controlled trial

    Wang, Xu, Xu, et al. · 2026 · Clinical medicine

    Primary claim

    no statistically significant difference in incidence of a composite of all cause dementia or mild cognitive impairment was observed among adults with type 2 diabetes receiving standard treatment of SBP and intensive treatment

    Well-supported
    Evidence Score
    4.1±0.1
    Reliability
    Caveats
  2. Smoking and dementia risk: an updated systematic review and meta-analysis of 61 prospective cohort studies and implications for tobacco control

    Mario Siervo, Jacob Brain, Sarah Beasley, et al. · 2026 · Health sciences

    Primary claim

    Current smoking was associated with increased risk of all-cause dementia (RR 1.31 [95% CI 1.23–1.39]; number of studies (k) = 39), Alzheimer's disease (1.40 [1.08–1.80]; k = 15), and vascular dementia (1.52 [1.20–1.93]; k = 9).

    Supported
    Evidence Score
    3.3±0.2
    Reliability
    Caveats
  3. Decreased awareness of cognitive decline is associated with multimodal Alzheimer's disease biomarkers in cognitively unimpaired individuals

    2026 · Clinical medicine

    Primary claim

    decreased ACD was associated with greater AD pathological burden

    Supported
    Evidence Score
    3.2±0.2
    Reliability
    Caveats

How the rubric works →